ScreenerHero

SLGL Sol-Gel Technologies Ltd.

NAS · US · Healthcare · Biotechnology · sol-gel.com
71.94USD-4.88%Mkt Cap: 235.55M $P/E: —

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap235.55M USD
Enterprise Value200.49M USD
Revenue (TTM)1.79M USD
Gross Profit-14.03M USD
Net Income (TTM)-6.13M USD
Revenue/Share0.61 USD
Last Price71.94 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees28
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.05
PEG—
EV/EBITDA-11.33
EV/Revenue111.69
P/S137.96
P/B5.15
EPS (TTM)-5.61
EPS (Forward)-8.36
52W Range
27.0063% of range97.97
52W High97.97 USD
52W Low27.00 USD
Profitability
Gross Margin0.00%
Oper. Margin-704.23%
EBITDA Margin0.00%
Profit Margin-31.60%
ROE-26.86%
ROA-20.48%
Growth
Revenue Growth-96.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF322.00K USD
CapEx (TTM)47.00K USD
FCF Margin-118.12%
FCF Yield-0.90%
Net Debt-47.16M USD
Net Debt/EBITDA2.67
Balance Sheet
Debt/Equity0.04
Current Ratio10.37
Quick Ratio9.87
Book Value/Sh14.69 USD
Cash/Share14.64 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateMay 5, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)152.50 USD
Upside (mean)+112.0%
Target Range110.00 USD – 195.00 USD
110.00+112.0% to mean195.00
# Analysts2
Ownership
Shares Out.3.27M
Float489.00K
Insiders59.66%
Institutions43.05%
Short Interest
Short Ratio1.9d
Short % Float11.55%
Short % Out.3.73%
Shares Short122.21K
Short (prev mo.)49.60K
Technical
SMA 5074.14 (-3.0%)
SMA 20072.08 (-0.2%)
Beta1.15
S&P 52W Chg15.78%
Avg Vol (30d)53.18K
Avg Vol (10d)47.77K
Technical Indicators
RSI (14)50.7
MACD0.1541
MACD Signal-1.3457
MACD Hist.+1.4998
BB Upper79.18 USD
BB Middle68.31 USD
BB Lower57.44 USD
BB Width31.83%
ATR (14)4.741 USD
Vol Ratio (20d)0.67x